Six New Companies Select SHYFT to Maximize Launch Success of Specialty and Rare Disease Brands
SHYFT Analytics, the leading data and analytics cloud for life sciences, today announced that in the last quarter, six biopharma companies have chosen to launch their new therapies using the SHYFT Platform. The number of SHYFT Launch customers has increased 50% year over year propelled by the company’s uniquely integrated cloud-based data companies and analytics solutions, which are specifically designed to meet the needs of manufacturers developing and launching complex therapies.
“More than half of newly launched drugs fail to meet market expectations. The success rate is even lower with Rare Disease and Specialty therapies, where smaller patient populations and complicated delivery make successful commercialization a challenge,” said Zack King, founder and CEO at SHYFT. “The SHYFT Platform is designed to overcome these challenges and is becoming the technology foundation for drug launches in life sciences. This allows our customers to drive greater efficiency and focus on innovation, not infrastructure as they launch important new therapies.”
SHYFT’s Launch Solution has seen increased adoption across customers, including four of the twenty largest biopharmaceutical companies. Rare and Specialty brands face unique challenges when launching new therapies, especially with regards to managing and making sense of complex data. They must manage a broad spectrum of distribution, commercial, and patient-level data to measure market execution and patient outcomes. The SHYFT Platform seamlessly integrates hundreds of data sources, including provider, payer, prescription, claims, and EMR data, into a unified cloud data platform answering complex clinical and commercial queries in minutes. Customers use SHYFT’s cloud platform and mobile analytic products to collaborate and engage their customers, identify and onboard patients, understand prescribing influences, and optimize treatment adherence and outcomes – a major transformation from legacy on-premise and expensive consulting-based solutions.